An estimated 3 million cases of C. difficile associated diarrhoea (CDAD) and colitis occur annually in the US, and the bacterium is believed to cause more deaths than traffic accidents in the UK. CDAD is a particularly serious illness, associated with the bacterium Clostridium difficile, and ranges from mild diarrhoea to life threatening conditions such as pseudomembranous colitis.
One of the main predisposing factors for the acquisition of CDAD is antibiotic therapy with broad spectrum antibiotics. When the normal bacteria living in the gut (the gut flora) are disturbed by antibiotics, C. difficile is able to proliferate and produce toxins that cause diarrhoea, lower abdominal pain and other symptoms such as nausea, fever and malaise. The problem is compounded by the fact that C. difficile forms spores which survive outside the body for long periods and are more resistant to chemical disinfectants. Patients with CDAD excrete large numbers of spores in their faeces; contaminating the hospital environment and spreading the disease.
Current treatments are largely confined to two potent antibiotics: metronidazole and vancomycin. However, treatment failures and relapses are common using these antibiotics. There is also a risk of spreading antibiotic resistance to other hospital pathogens.
The APC research team is investigating the potential of an antimicrobial peptide discovered in Cork as a novel therapeutic for the treatment of CDAD. Lacticin 3147 is produced by a harmless bacterium, Lactococcus lactis, one of a number of bacteria used by cheesemakers for millennia. When lacticin was tested against strains of C. difficile isolated from patients with diarrhoea or inflammatory bowel disease or healthy adults it was shown to be as effective as the antibiotics currently in use. This study, which is published in the current issue of Journal of Medical Microbiology, demonstrates that the potent antimicrobial lacticin can kill this dangerous pathogen at relatively low concentrations. Moreover, the team go on to show that lacticin is effective in killing the pathogen in contaminated faeces and suggest lacticin may be the basis for future therapies against the infection. The research is now focussing on optimising the delivery of lacticin to the colon and the potential for co-administration of lacticin-tolerant probiotics to restore a healthy gut flora.
Reference : Mary Rea et al., Journal Medical Microbiology (2007) 56, 940-946.
Catherine Buckley | alfa
Second cause of hidden hearing loss identified
20.02.2017 | Michigan Medicine - University of Michigan
Prospect for more effective treatment of nerve pain
20.02.2017 | Universität Zürich
In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport
Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...
The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.
The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...
Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...
Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".
Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...
13.02.2017 | Event News
10.02.2017 | Event News
09.02.2017 | Event News
20.02.2017 | Materials Sciences
20.02.2017 | Health and Medicine
20.02.2017 | Health and Medicine